In conclusion, monitoring of WT1 mRNA, which can be easily evaluated through PB sampling, could be a universal MRD marker for almost all AML patients treated with VEN combination therapy to predict disease prognosis. The gene discussed is WT1; the disease is acute myeloid leukemia.